Sun Pharma to Share Crucial Long-Term Data on UNLOXCYT at ASCO 2026 Annual Meeting

Sun Pharma to Present Pivotal Data on UNLOXCYT at ASCO 2026

At the upcoming ASCO 2026 Annual Meeting, taking place on May 31 in Chicago, Sun Pharmaceutical Industries Limited is set to reveal groundbreaking data regarding its innovative treatment, UNLOXCYT™ (cosibelimab-ipdl). This presentation will focus specifically on long-term follow-up results from a significant expansion cohort of patients suffering from locally advanced cutaneous squamous cell carcinoma (laCSCC), a common but serious form of skin cancer.

Study Overview

The pivotal CK-301-101 trial analysis highlighted at ASCO will primarily present findings from a cohort of 64 patients who received at least one dose of UNLOXCYT. This cohort exhibited a median age of 77 years, with 66% of the group being male. Such demographics align with those frequently observed in clinical practice, indicating the study's relevance to real-world scenarios. Each patient underwent a median treatment duration of 60 weeks, with a median of 29 doses administered so far.

Notably, the objective response rate (ORR) came in at 50%. Of these patients, 27% achieved a complete response, while another 23% recorded partial responses. The data not only reflects efficacy but also reveals the durability of these responses; many patients continued to show positive results even over a median follow-up period of 31 months.

According to Dr. Rahul Ladwa, a medical oncologist involved in the study, the data emphasizes clinically meaningful efficacy within the laCSCC patient population. He highlighted how the observed high rates of complete responses are associated with long-term clinical outcomes, which represents a crucial therapeutic goal. Furthermore, the safety profile remains manageable, mirroring earlier analyses of a smaller cohort, which adds to the credibility of these findings.

Safety Profile

In terms of safety, the side effects reported were primarily anemia and diarrhea, affecting 27% of participants each. Meanwhile, immune-related adverse reactions (irAEs) occurred in 34% of patients, with grade 3 irAEs observed in just 2%—largely resulting in dermatological symptoms such as rashes. Treatment-emergent adverse events (TEAEs) were noted in 95% of patients, but strikingly, none of these cases were fatal.

Dr. Emily Ruiz, an associate professor of dermatology at Harvard Medical School and another co-author of the study, praised the results not only for their efficacy but also for their tolerability. Given that many laCSCC patients are older and often grapple with various comorbid conditions, developing treatment options that are both effective and well-tolerated is of utmost importance.

Innovative Mechanism of Action

UNLOXCYT operates differently from standard checkpoint inhibitors by re-establishing the adaptive immune response and engaging the innate immune system while preserving the PD-1/PD-L2 pathway. This distinct mechanism potentially explains the positive results observed in the patient cohort.

Anticipated Presentation Details

The presentation of this research will occur during a poster session on Melanoma/Skin Cancers, specifically under the abstract number 9585, taking place at the poster board number 301. Dr. Rahul Ladwa is expected to present these pivotal findings, further emphasizing the importance of the research within the oncology community.

Ahmad Naim, MD, Senior Vice President and Chief Medical Officer at Sun Pharma, expressed enthusiasm about showcasing these crucial data at ASCO, stating they reinforce the company’s commitment to the skin cancer community. With over two and a half years of follow-up, UNLOXCYT continues to exhibit clinically meaningful efficacy along with durable clinical responses—a much-needed option for patients battling laCSCC.

About UNLOXCYT and Cutaneous Squamous Cell Carcinoma

UNLOXCYT is specifically indicated for adults diagnosed with metastatic cutaneous squamous cell carcinoma (mCSCC) or locally advanced CSCC (laCSCC) who are not candidates for curative surgical options or radiation therapy. Its recommended dosage is 1,200 mg via intravenous infusion over a period of 60 minutes every three weeks.

Cutaneous squamous cell carcinoma is among the most prevalent skin cancers globally, particularly affecting those with chronic UV radiation exposure or who are immunocompromised. While early forms are typically manageable, approximately 40,000 U.S. patients transition to advanced stages annually, leading to around 15,000 deaths.

Sun Pharma remains focused on advancing treatment for skin cancers through collaborative efforts and innovative research, underlining their commitment to improving the lives of those affected by skin oncology.